David Greenwald, MD
Hematology & Oncology · Kingston, PANPI 1558380295
Payments from drug & device makers
Across 193 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$519
- Pfizer$470
- Genentech USA, Inc.$271
- Bristol Myers Squibb$197
- Astellas Pharma US Inc$189
- Pharmacyclics LLC, An Abbvie Company$186
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,33289%
- Education$40211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $519 |
| Pfizer | 33 | $470 |
| Genentech USA, Inc. | 12 | $271 |
| Bristol Myers Squibb | 11 | $197 |
| Astellas Pharma US Inc | 11 | $189 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $186 |
| Merck | 10 | $147 |
| Gilead(2 entities) | 9 | $145 |
| AbbVie | 7 | $144 |
| Seagen Inc. | 3 | $137 |
| Array Biopharma Inc | 8 | $130 |
| Intuitive Surgical | 1 | $128 |
| AstraZeneca(2 entities) | 4 | $122 |
| GSK | 5 | $111 |
| Sanofi | 6 | $95 |
| Daiichi Sankyo Inc. | 4 | $87 |
| Amgen | 4 | $68 |
| Bayer | 3 | $50 |
| Taiho Oncology, Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| AVEO Pharmaceuticals, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Foundation Medicine, Inc. | 2 | $29 |
| Shield Therapeutics Inc | 1 | $29 |
| Puma Biotechnology, Inc. | 1 | $27 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Beigene USA, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Mylan Institutional Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $14 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Heron Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,735 in reported general payments places this provider in the 45th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 111 | $1,754,828 |
| ImbruvicaIbrutinib | 45 | $724,131 |
| LenvimaLenvatinib Mesylate | 18 | $632,316 |
| RevlimidLenalidomide | 26 | $545,378 |
| Abiraterone Acetate | 130 | $384,196 |
| XtandiEnzalutamide | 33 | $320,130 |
| CalquenceAcalabrutinib Maleate | 22 | $316,780 |
| TagrissoOsimertinib Mesylate | 18 | $310,124 |
| MekinistTrametinib Dimethyl Sulfoxide | 26 | $223,615 |
| Lenalidomide | 19 | $210,445 |
| BrukinsaZanubrutinib | 12 | $173,195 |
| TafinlarDabrafenib Mesylate | 17 | $161,056 |
| JaypircaPirtobrutinib | 11 | $123,697 |
| Sunitinib Malate | 19 | $102,298 |
| Imatinib Mesylate | 65 | $87,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $470 | $1,763,006126 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $186 | $724,13145 claims |
| Eisai Inc.Lenvima | $18 | $632,31618 claims |
| AstraZenecaCalquence, Tagrisso | $122 | $626,90440 claims |
| Bristol Myers SquibbRevlimid | $197 | $545,37826 claims |
| NovartisMekinist, Tafinlar | $519 | $384,67043 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $189 | $327,28847 claims |
| Beigene USA, Inc.Brukinsa | $23 | $173,19512 claims |
| Lilly USA, LLCJaypirca | $35 | $123,69711 claims |
| AmgenXgeva | $68 | $48,32615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Kingston
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.